Canada - Cisatracurium (E60PH-20CTRA/B)

Description

Trade Agreement: NONE
Tendering Procedures: All interested suppliers may submit a bid
Competitive Procurement Strategy: N/A - P&A/LOI Only
Comprehensive Land Claim Agreement: No
Nature of Requirements:

*This is an extension of the original request which closed on May 8, 2020. If you responded to the original RFI, there is no requirement to resubmit.*

The Government of Canada recognizes that Canadians who are ill with COVID-19 need access to safe and effective medicines and treatments. As such, the Government of Canada is actively monitoring the impact of the COVID-19 pandemic on the supply of drugs in Canada.

Through this Request for Information (RFI), Canada is seeking to collect information from companies to inform the Government’s response to the ongoing pandemic.

The priority of the Government of Canada is to ensure that there remains a stable supply of treatments for those patients who require as currently approved by Health Canada.

This request is a tool to identify additional supply that has not already been earmarked to meet Canada’s current needs. The Government of Canada is interested in procuring up to a twelve-month supply which would support existing efforts to ensure Canadians have access to the drugs they need. In light of ongoing fluctuations in global and domestic demand, should the Government proceed, an incremental procurement approach would be considered.

Please Note: If your company is currently working with the Government of Canada to address an existing shortage, we are not looking for information on products already identified to mitigate the shortage. The Government of Canada is also interested in receiving information about acceptable substitute drugs.

If your company is not currently working with the Government of Canada to address an existing shortage, or if you are working with Health Canada but may have access to additional product, we would welcome information on available Cisatracurium or equivalent product. We are looking to ensure this drug is available for Canadians without affecting the supply currently available for the Canadian market through existing distribution channels.

The Government of Canada is aware that there are risks of drug shortages globally due to the pandemic and that the current drug shortages faced by Canada are not unique. As such, many jurisdictions are seeking to access the supply from many of the same sources. The Government of Canada remains committed to working with its international partners on the issue of drug shortages to stabilize global supply chains as quickly as possible.

Delivery Date: 09/05/2020

The Crown retains the right to negotiate with suppliers on any procurement.

Documents may be submitted in either official language of Canada.

Opportunity closing date

27 May 2020

Value of contract

to be confirmed